Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariohysterectomized Beagle Dogs: Effects on Bone Morphometry and Mineral Properties
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Bisphosphonates have emerged as a valuable treatment for postmenopausal osteoporosis. Bisphosphonate treatment is usually accompanied by a 3–6% gain in bone mineral density (BMD) during the first year of treatment and by a decrease in bone turnover. Despite low bone turnover, BMD continues to increase slowly beyond the first year of treatment. There is evidence that bisphosphonates not only increase bone volume but also enhance secondary mineralization. The present study was conducted to address this issue and to compare the effects of continuous and intermittent bisphosphonate therapy on static and dynamic parameters of bone structure, formation, and resorption and on mineral properties of bone. Sixty dogs were ovariohysterectomized (OHX) and 10 animals were sham-operated (Sham). Four months after surgery, OHX dogs were divided in six groups (n = 10 each). They received for 1 year ibandronate daily (5 out of 7 days) at a dose of 0, 0.8, 1.2, 4.1, and 14 μg/kg/day or intermittently (65 μg/kg/day, 2 weeks on, 11 weeks off). Sham dogs received vehicle daily. At month 4, there was a significant decrease in bone volume in OHX animals (p < 0.05). Doses of ibandronate ≥ 4.1 μg/kg/day stopped or completely reversed bone loss. Bone turnover (activation frequency) was significantly depressed in OHX dogs given ibandronate at the dose of 14 μg/kg/day. This was accompanied by significantly higher crystal size, a higher mineral-to-matrix ratio, and a more uniformly mineralized bone matrix than in control dogs. This finding lends support to the hypothesis that an increase in secondary mineralization plays a role in gain in BMD associated with bisphosphonate treatment. Moreover, intermittent and continuous therapies had a similar effect on bone volume. However, intermittent therapy was more sparing on bone turnover and bone mineral properties. Intermittent therapy could therefore represent an attractive alternative approach to continuous therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Cummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277 · cited 2×
“Despite a state of low bone turnover, a smaller but progressive increase in bone mass occurs beyond the first year of bisphosphonate therapy.((5,7,15,18,29,30))”
BackgroundSato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., & Rodan, G. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115539 · Cited by 1,004 · cited 1×
“However, other in vitro studies showed that aminobisphosphonates such as alendronate are not cytotoxic((75)) and do not alter osteoclast number.((76)) These data, together with the histomorphometric findings, suggest that bisphosphonates act in vivo primarily on osteoclast activity.”
ResultBalena, R., Toolan, B. C., Shea, M., Markatos, A., Myers, E. R., Lee, S. C., Opas, E. E., Seedor, J. G., Klein, H., & Frankenfield, D. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116872 · Cited by 396 · cited 1×
“This discrepancy between osteoclastic activity (erosion depth) and eroded surface was also noted in cortical bone of dogs treated with risedronate,((69)) in ovariectomized baboons given alendronate,((12)) and in postmenopausal women treated with etidronate((70)) or alendronate.”
BackgroundBM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Mühlbauer, R. C., Bauss, F., Schenk, R., Janner, M., Bosies, E., Strein, K., & Fleisch, H. (1991) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650060915 · Cited by 239 · cited 2×
“It prevents retinoid-induced hypercalcemia in thyroparathyroidectomized rats at lesser doses than risedronate (2×), alendronate (10×), pamidronate (50×), and clodronate (500×).((37)) Also, we have previously demonstrated that ibandronate at the low dose of 1 mg/kg was able to prevent completely the bone loss occurring…”
BackgroundResultSelf-citation
Cited by
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Bisphosphonates: Mode of Action and Pharmacology
Russell, R. G. G. (2007) · Pediatrics · doi:10.1542/peds.2006-2023h · Cited by 503
Bone composition: relationship to bone fragility and antiosteoporotic drug effects
Boskey, A. L. (2013) · BoneKEy Reports · doi:10.1038/bonekey.2013.181 · Cited by 424
Self-citationBisphosphonates: From Bench to Bedside
RUSSELL, R. G. G. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1346.041 · Cited by 410
Infrared Assessment of Bone Quality: A Review
Paschalis, E. P., Mendelsohn, R., & Boskey, A. L. (2011) · Clinical Orthopaedics & Related Research · doi:10.1007/s11999-010-1751-4 · Cited by 215
“in evaluating various therapeutic protocols, providing insight into the mechanisms by which the various drugs work and therefore assisting in the design of new and more targeted ones [7, 13, 17, 22, 26, 49, 52, 55, 56, 58, 62, 71].”
Self-citation
Metadata
- Authors
- Monier-Faugere, M.-C., Geng, Z., Paschalis, E. P., Qi, Q., Arnala, I., Bauss, F., Boskey, A. L., & Malluche, H. H.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-10-01
- Volume
- 14
- Issue
- 10
- Pages
- 1768-1778
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2089272876
- Cited by
- 94
- References
- 5
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariohysterectomized Beagle Dogs: Effects on Bone Morphometry and Mineral Properties. https://app.cochat.ai/papers/10.1359/jbmr.1999.14.10.1768
- The paper
- Monier-Faugere, M.-C., Geng, Z., Paschalis, E. P., Qi, Q., Arnala, I., Bauss, F., Boskey, A. L., & Malluche, H. H. (1999). Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariohysterectomized Beagle Dogs: Effects on Bone Morphometry and Mineral Properties. Journal of Bone and Mineral Research. https://doi.org/10.1359/jbmr.1999.14.10.1768
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.